Format

Send to

Choose Destination
Hybridoma. 1997 Aug;16(4):381-9.

Rapid development of affinity matured monoclonal antibodies using RIMMS.

Author information

1
Department of Molecular Sciences, Glaxo Wellcome, Research Triangle Park, NC 27709, USA.

Abstract

Affinity matured murine monoclonal antibody producing cell lines can now be rapidly generated using a novel repetitive, multiple site immunization strategy designated RIMMS. RIMMS capitalizes on rapid hypermutation and affinity maturation events which occur in B cell populations localized within secondary lymphatic tissue early in response to antigenic challenges. A murine myeloma cell line, P3XBcl-2-13, stably transfected with Bcl-2, enhances the outgrowth of hybridomas following somatic fusion with immune lymphocytes isolated from pooled peripheral lymph nodes (PLN) 8-14 days after the initial immunization. Immunizations somatic fusion, screening and isolation of affinity matured IgG secreting monoclonal antibody cell lines occur within a one month time period. By using RIMMS, we have been able to expedite the isolation of affinity matured monoclonal antibodies to numerous antigens, including a drug hapten.

PMID:
9309429
DOI:
10.1089/hyb.1997.16.381
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center